Citius Pharmaceuticals shares fall 38.59% intraday as GAAP earnings miss estimates and 10-K highlights commercialization risks.

Citius Pharmaceuticals plummeted 38.59% intraday as the company reported 2025 fiscal year GAAP earnings of -$3.38 per share, below analysts' expectations of $0.25, and disclosed in its 10-K filing limited commercialization capabilities, including reliance on Citius Oncology and risks associated with the recent LYMPHIR product launch.